Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does β-lactam class matter?

Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does β-lactam class matter? Antimicrob Agents Chemother. 2019 Jan 07;: Authors: Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC Abstract We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (COMBO) on persistent methicillin-resistant Staphylococcus aureus bacteremia (≥5 days) compared to VAN using pooled data from two previously published, observational studies (n=156). COMBO was inversely associated with persistent bacteremia (adjusted odds ratio 0.460, 95% confidence interval, 0.229-0.923). Acute kidney injury was more common in COMBO than VAN (18.9% and 7.6%, respectively; p=0.062). PMID: 30617094 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research